In Brief: Conmed
This article was originally published in The Gray Sheet
Conmed: Completes proposed acquisition of Bristol-Myers Squibb's Linvatec/Hall orthopedic surgery subsidiary Dec. 31. Terms of the deal, which was announced in early December ("The Gray Sheet" Dec. 8, p. 13), include $370 mil. in cash and a 10-year warrant allowing BMS to purchase one million shares of Conmed common stock at $34.23 per share. Conmed will take a one-time charge in connection with the purchase...
You may also be interested in...
To be more transparent and allow more public discourse, the HHS now requires all its agencies to publish documents it uses to rationalize proposed rules and demonstration projects.
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from India's Glenmark.
Second read-out maintains 94% level of efficacy, with a very early signal that it could outperform Pfizer’s rival mRNA candidate in preventing severe cases.